<DOC>
	<DOCNO>NCT01878617</DOCNO>
	<brief_summary>Historically , medulloblastoma treatment determine amount leftover disease present surgery , also know clinical risk ( standard vs. high risk ) . Recent study show medulloblastoma make distinct molecular subgroup respond differently treatment . This suggest clinical risk alone adequate identify actual risk recurrence . In order address , stratify medulloblastoma treatment phase II clinical trial base clinical risk ( low , standard , intermediate , high risk ) molecular subtype ( WNT , SHH , Non-WNT Non-SHH ) . This stratified clinical molecular treatment approach use evaluate following : - To find participant low-risk WNT tumor treat low dose radiation brain spine , low dose chemotherapy drug cyclophosphamide still achieve survival rate past St. Jude study fewer side effect . - To find add targeted chemotherapy standard chemotherapy benefit participant SHH positive tumor . - To find add new chemotherapy agent standard chemotherapy improve outcome intermediate high risk Non-WNT Non-SHH tumor . - To define cure rate standard risk Non-WNT Non-SHH tumor treat reduce dose cyclophosphamide compare participant past St. Jude study . All participant study surgery remove much primary tumor safely possible , radiation therapy , chemotherapy . The amount radiation therapy type chemotherapy receive determined participant 's treatment stratum . Treatment stratum assignment base tumor 's molecular subgroup assignment clinical risk . The participant assign one three medulloblastoma subgroup determine analysis tumor tissue tumor biomarkers : - WNT ( Strata W ) : positive WNT biomarkers - SHH ( Strata S ) : positive SHH biomarkers - Non-WNT Non-SHH , Failed , Indeterminate ( Strata N ) : negative WNT SHH biomarkers result indeterminable Participants assign clinical risk group ( low , standard , intermediate , high ) base assessment : - How much tumor leave surgery - If cancer spread site outside brain [ i.e. , spinal cord within fluid surround spinal cord , call cerebrospinal fluid ( CSF ) ] - The appearance tumor cell microscope - Whether chromosomal abnormality tumor , present , type ( also call cytogenetics analysis )</brief_summary>
	<brief_title>A Clinical Molecular Risk-Directed Therapy Newly Diagnosed Medulloblastoma</brief_title>
	<detailed_description>Primary Objectives : - To estimate progression free survival distribution WNT-medulloblastoma patient treat Stratum W1 reduced-dose craniospinal irradiation reduced-dose cyclophosphamide . - To estimate progression-free survival distribution Non-WNT Non-SHH medulloblastoma patient treat Stratum N1 reduce dose cyclophosphamide . - To evaluate effect aerobic training intervention , deliver radiation therapy period home , prior start chemotherapy , cardiopulmonary fitness . - To assess impact computer-based work memory intervention ( administer prophylactically end chemotherapy ) , relative standard care , performance-based measure work memory . Secondary Objectives : - To estimate overall survival distribution WNT-medulloblastoma patient treat Stratum W1 reduced-dose craniospinal irradiation reduced-dose cyclophosphamide compare progression free overall survival distribution molecularly clinically matched historical control St. Jude SJMB03 study . - To estimate progression free overall survival distribution SHH medulloblastoma patient enrol Strata S1 S2 treat oral maintenance therapy use target SHH pathway inhibitor ( vismodegib ) adjuvant chemotherapy regimen complete compare progression-free overall survival distribution molecularly clinically matched historical control St. Jude SJMB03 study . - To estimate progression free overall survival distribution Non-WNT Non-SHH medulloblastoma patient treat Strata N2 N3 3 cycle pemetrexed gemcitabine addition 4 cycle conventional adjuvant chemotherapy compare progression-free overall survival distribution molecularly clinically matched historical control St. Jude SJMB03 study separately stratum . - To estimate overall survival distribution Non-WNT Non-SHH medulloblastoma patient treat Stratum N1 reduce dose cyclophosphamide compare progression free overall survival distribution molecularly clinically matched historical control St. Jude SJMB03 study . - To evaluate feasibility toxicity add pemetrexed gemcitabine adjuvant chemotherapy regimen intermediate high risk Non-WNT Non-SHH medulloblastoma patient ( Strata N2 N3 ) . - To evaluate feasibility toxicity oral maintenance therapy target SHH inhibitor ( vismodegib ) conventional adjuvant chemotherapy regimen complete . - To estimate cumulative incidence local disease failure 2 5 year base treatment regimen , stratum , clinical treatment factor . - To evaluate effect aerobic train intervention , deliver radiation therapy period home , prior start chemotherapy , physical performance , fatigue , health relate quality life , memory , attention executive function end intervention , end adjuvant chemotherapy , one , two five year adjuvant chemotherapy , among child treat medulloblastoma . - To evaluate impact aerobic training intervention sleep quality quantity child medulloblastoma . - To evaluate relation baseline cognitive performance variable sleep quality quantity , fatigue child medulloblastoma . - To estimate change neurocognitive performance use comprehensive assessment battery ( e.g. , measure intellectual function , academic ability , attention , memory , process speed executive function ) investigate relationship change relevant demographic factor ( e.g. , gender , age treatment , time since treatment socioeconomic status ) clinical factor ( e.g. , treatment intensity/risk group , posterior fossa syndrome ) . - To assess impact computer-based work memory intervention , relative standard care , additional performance- rater-based measure attention , process speed executive function . - To compare impact computer-based work memory intervention conjunction aerobic training intervention , relative either intervention isolation , measure attention , process speed executive function . - To evaluate maintenance improvement measure attention , work memory , process speed executive function six month follow participation computer-based work memory intervention program . Outline : This multicenter study . Patients stratify accord molecular subgroup assignment ( WNT , SHH , Non-WNT Non- SHH ) clinical risk stratification ( extent resection , M stage , histologic subtype , cytogenetic feature ) . All patient treat risk-adapted radiation therapy adjuvant chemotherapy . Patients assign Stratum W1 receive reduce dose radiation therapy . Patients assign Stratum W2 , S1 , N1 , N2 receive standard dose radiation therapy . Patients assign Stratum W3 , S2 , N3 receive high dose radiation therapy . Radiation therapy follow 4 cycle adjuvant conventional chemotherapy cyclophosphamide , cisplatin vincristine patient . Patients assign Stratum N2 N3 ( Non-WNT Non-SHH high risk factor ) receive 3 additional cycle pemetrexed gemcitabine chemotherapy intermixed conventional adjuvant chemotherapy cycle . Patients SHH subtype ( Stratum S1 S2 ) skeletally mature receive 12 month additional maintenance therapy vismodegib . Patients may consent provide tumor tissue , blood , CSF sample biological study . Tumor tissue analyze activation WNT signal pathway , activation SHH signal pathway , validation novel pattern gene expression via immunohistochemical ( IHC ) analysis ; validation genetic abnormality via interphase fluorescence situ hybridization ( iFISH ) ; construction gene expression profile via microarray analysis ; construction DNA methylation profile via microarrays ; single nucleotide polymorphism ( SNP ) analysis DNA copy number aberration ; potential oncogene tumor suppressor gene via DNA sequence analysis ; expression number cell signal protein implicate biology medulloblastoma via western blot ; expression additional protein encode gene associate SNP gene expression array analysis clinical disease behavior . Blood sample analyze patient whose tumor contain gene mutation via sequence analysis constitutional DNA . CSF blood sample analyze identification potential tumor marker . Parents may consent blood sample analyze inheritable gene mutation associate medulloblastoma . Patients may also consent exploratory research include additional functional MRI image investigate damage neural connection therapy ; additional psychological testing identify neurocognitive effect therapy ; additional heart lung test identify treatment effect ; additional endocrine study identify treatment effect growth development . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>INCLUSION CRITERIA Medulloblastoma medulloblastoma variant include posterior fossa PNET document institutional pathologist . Age great equal 3 year less 22 year age time diagnosis . No previous radiotherapy , chemotherapy brain tumor direct therapy corticosteroid therapy surgery . Patients must begin treatment outline protocol within 36 day definitive surgery ( day surgery day 0 ; definitive surgery include second surgery resect residual tumor ) . Adequate performance status : child &lt; 10Lansky Score ≥ 30 ; child ≥ 10Karnofsky ≥ 30 ( except posterior fossa syndrome ) . Females childbearing potential pregnant breastfeeding . Female participant &gt; 10 year age postmenarche must negative serum urine pregnancy test prior enrollment . Biological parent ( ) participant ( child ) enrol protocol . These parent assign cohort P. The exclusion criterion apply cohort . EXCLUSION CRITERIA CNS embryonal tumor medulloblastoma PNET posterior fossa , example , patient diagnosis Atypical Teratoid / Rhabdoid Tumor ( ATRT ) , supratentorial PNET , pineoblastoma , ependymoblastoma , ETANTR exclude . Research participants clinically significant medical disorder could compromise ability tolerate protocol therapy would interfere study procedure result history . Participants Stratum S maintenance chemotherapy portion study must meet criterion prior start vismodegib therapy : Must &gt; 10 year time start maintenance Must skeletally mature define female bone age ≥ 15 year males bone age ≥ 17 year Must agree effective contraception participant reproductive potential Participants exercise intervention portion study must meet criterion : Must &gt; 5 year time enrollment Must congenital heart disease Must capable performing exercise intervention time baseline assessment determine treat physician . Participants cognitive remediation intervention portion study must meet criterion : Completed protocoldirected radiation therapy ≥5 year time remediation intervention consent English primary language training aide speak English available participate require session No significant cognitive impairment operationalized either IQ &lt; 70 child St. Jude SJMB12 study baseline test base clinician judgment baseline IQ miss No major sensory motor impairment would preclude valid cognitive testing ( e.g. , unresolved posterior fossa syndrome , blindness , poorly control seizures/photosensitive epilepsy , psychosis ) major psychological condition would preclude completion intervention ( e.g. , significant oppositionality , autism spectrum disorder , severe anxiety depressive symptom )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SJMB12</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumors Children</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Embryonal Tumors CNS</keyword>
	<keyword>GDC-0449</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Hedgehog Pathway Inhibitor</keyword>
	<keyword>Infratentorial</keyword>
	<keyword>Mass Brain</keyword>
	<keyword>Medulloblastoma</keyword>
	<keyword>Medulloblastoma Brain Tumor</keyword>
	<keyword>Medulloblastoma Tumor</keyword>
	<keyword>Molecular</keyword>
	<keyword>Neuroectodermal Tumor , Primitive</keyword>
	<keyword>Newly Diagnosed Childhood Medulloblastoma</keyword>
	<keyword>Non-SHH Non-WNT</keyword>
	<keyword>Pediatric Brain Tumor</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Posterior Fossa Tumor</keyword>
	<keyword>Proton Beam Therapy</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Rare Brain Tumor</keyword>
	<keyword>Risk</keyword>
	<keyword>SHH</keyword>
	<keyword>Sonic Hedgehog Pathway</keyword>
	<keyword>St Jude Medullo</keyword>
	<keyword>St. Jude Brain Tumor Studies</keyword>
	<keyword>St. Jude Medullo</keyword>
	<keyword>St. Jude Studies</keyword>
	<keyword>St. Jude Treatment</keyword>
	<keyword>Treatment Brain Tumors Children</keyword>
	<keyword>Untreated Childhood Medulloblastoma</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Vismodegib</keyword>
	<keyword>WNT</keyword>
</DOC>